

22 October 2025

Patient recruitment in US-veteran focused mental health trial complete

Highlights:

- 60 patients enrolled in US Veteran focused mental health trial marking completion of recruitment
- Trial uses TRI's single-channel algorithm which utilises heart rate and heart rate variability to accurately conduct sleep staging and screen for current Major Depressive Episode
- Trial undertaken alongside the Greater Los Angeles Research and Education Foundation (GLAVREF) and US Veterans Affairs (VA) Greater Los Angeles Healthcare System
- Completion of 60 patient recruitment follows promising interim results taken from 27 of first 30 patients
- Additional results expected this quarter – Positive results will form the basis of commercial engagement with key partner groups and regulatory engagement

Perth, Australia, and Minneapolis, USA: TrivarX Limited ('the Company') (ASX: TRI) is pleased to advise it has completed patient recruitment in its clinical trial alongside the Greater Los Angeles Research and Education Foundation (GLAVREF) and US Veterans Affairs (VA) Greater Los Angeles Healthcare System evaluating its novel single-lead ECG algorithm to screen for current major depressive episodes (cMDE) in veterans with suspected sleep apnoea (refer ASX Announcement 28 April 2025).

The single-channel ECG algorithm used in the trial is an extension of MEB-001. The algorithm accurately performs sleep staging and detects cMDE in subjects using only heart rate (HR) and heart rate variability (HRV) metrics.

The 60 patients were enrolled at the West Los Angeles VA Medical Center. Each patient has now completed an overnight polysomnography (PSG) sleep study and a Mini International Neuropsychiatric Interview (MINI), which was administered by qualified health professionals.

Completion of patient recruitment follows positive interim results, taken from 27 of the 30 participants enrolled through the VA Greater Los Angeles Healthcare System (refer ASX announcement: 8 October 2025). This interim analysis highlighted similar performance between MEB-001 and the single-lead algorithm, underpinning additional validation for the Company's innovative single-lead offering.

The Company will now work alongside Principal Investigator, Dr Jennifer Martin to review all data associated with the final patient cohort. TrivarX expects that full results from the trial will be provided later this quarter.

Management commentary:

Non-executive Chairman, David Trimboli said: *"The completion of patient recruitment in our veteran-focused mental health trial marks an important milestone, building on the positive interim data already observed. This achievement reflects the strong collaboration with our partners at the VA and GLAVREF and demonstrates continued momentum in validating our single-lead algorithm as a scalable, non-invasive tool for mental-health assessment. We now look forward to reviewing the full data set and advancing discussions with potential partners and regulators to progress the technology's clinical and commercial potential."*

ASX ANNOUNCEMENT



Next steps:

TrivarX expects full trial results from the veteran-focused study to be finalised later this quarter, which will form the basis for engagement with regulatory agencies and commercial partners.

This announcement is authorised for release by the Board of Directors of TrivarX Limited.

ENDS

Investor Enquiries:

Henry Jordan – Six Degrees Investor Relations

Henry.jordan@mdir.com.au

+61 431 271 538

About TrivarX Limited:

TrivarX (ASX: TRI) (OTCPINK: MDBIF) is a mental health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. The Company was founded in Australia, with offices located in Perth (WA) and Minneapolis (MN, USA). TrivarX is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.otcm Markets.com and www.asx.com.au